Next week on the stock market

Aarin Chiekrie | 26 January 2024

Some links in this article may take you to Hargreaves Lansdown’s main website for more information. Please be aware that some of the benefits offered by your company Plan may require you to return to this website to apply. If at all unsure, please contact us.

Next week on the stock market

What to expect from a selection of FTSE 100, FTSE 250 and selected other companies reporting next week:

  • Novo Nordisk - will investments in production lift the lid on 2024 growth guidance?
  • We’ll find out if fourth-quarter cash flows have clammed up for Shell
  • Diageo will be hoping to avoid any more earnings disappointments



If you'd like to receive weekly shares content from us, sign up to our Share Insight email.

Among those currently scheduled to release results next week:

29-Jan
No FTSE 350 Reporters
30-Jan
Alphabet* Full Year Results
Diageo* Half Year Results
Microsoft* Q2 Results
Pets at Home* Q3 Results
Pfizer* Full Year Results
SSP Group Q1 Trading Statement
Sthree Full Year Results
31-Jan
Abrdn Private Equity Opportunities Trust Full Year Results
GSK* Q4 Results
Novo Nordisk* Full Year Results
01-Feb
3i Group Q3 Operational Performance
3i Infrastructure Q1 Trading Statement
AG Barr* Full Year Trading Statement
Airtel Africa Q3 Results
Amazon* Full Year Results
Apple* Q1 Results
Cranswick Q3 Trading Statement
Glencore Full Year Production Report
JTC Q1 Trading Statement
Meta* Full Year Results
Rightmove Full Year Results
Shell* Full Year Results
02-Feb
Chevron* Full Year Results

*Events on which we will be updating investors.

Novo Nordisk – Derren Nathan, Head of Equity Research

Novo Nordisk’s growth of late has been propelled by sales of its GLP-1 medicines in diabetes, with even stronger momentum in obesity care. We look forward to full year numbers next week, where the latest guidance suggests an increase of 32-38% for sales and 40-46% for operating profit.

The forthcoming results provide an opportunity for Novo to set initial guidance for 2024. We hope to hear how investments in manufacturing are relieving production bottlenecks. We’ll also be looking out for an update on the regulatory pathway for a once weekly insulin injection for diabetics, IcoSema, which has recently seen positive clinical trials data.

See the Novo Nordisk share price, charts and our latest view

Sign up to Novo Nordisk research

Shell – Derren Nathan, Head of Equity Research

We’re not expecting to see a dip in oil & gas production in Shell’s fourth quarter numbers next week. However, lower refinery utilisation and weaker commodities prices have the potential to dent cash flows.

Volatile pricing is part and parcel of being an energy company. However, an increased commitment to shareholder distributions and significant investment plans in both traditional and renewable energy means that there’s growing competition for funds. Meanwhile, there’s been mounting pressure for Shell to double down on its renewable commitments. So, we’ll be keeping a close eye on Shell’s plans to allocate its cash in 2024.

See the Shell share price, charts and our latest view

Sign up to Shell research

Diageo – Aarin Chiekrie, Equity Analyst

Back in November 2023, Diageo shocked markets by warning that this year’s revenue and profit would both be lower than expected. This came as performance in its Latin America and Caribbean region was materially weaker than anticipated, with first-half organic sales set to decline by more than 20%. Because of this, first-half operating profit looks set to fall around 4.3% to £3.6bn when the group reports next week.

In the group’s other major regions, momentum is expected to remain positive, with sales rising across the board. The Guinness brewer has a strong portfolio of brands under its belt, which should help it to return to 5-7% organic sales growth over the medium term. We’ll be keeping a close eye on the demand picture, with any further weakness likely to bring this guidance into question.

See the Diageo share price, charts and our latest view

Sign up to Diageo research

Unless otherwise stated estimates are a consensus of analyst forecasts provided by Refinitiv. These estimates are not a reliable indicator of future performance. Past performance is not a guide to the future. Investments rise and fall in value so investors could make a loss.

This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.

Share Insight: our weekly email

Sign up to receive weekly shares content from HL.

Please correct the following errors before you continue:

    Existing client? Please log in to your account to automatically fill in the details below.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Loading

    Your postcode ends:

    Not your postcode? Enter your full address.

    Loading

    Hargreaves Lansdown PLC group companies will usually send you further information by post and/or email about our products and services. If you would prefer not to receive this, please do let us know. We will not sell or trade your personal data.

    What did you think of this article?

    Hargreaves Lansdown Asset Management is authorised and regulated by the Financial Conduct Authority.

    Cookie policy | Disclaimer | Important Investment Notes | Terms & Conditions | Privacy Notice